biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 1/2019 | 29-01-2019 | Status projektu BacterOMIC – zakończenie trzeciego etapu prac nad projektem

Previous PostNext Post

Related Posts

30.09.2026

Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors

0
28.09.2026

Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations

0
08.09.2026

Scope Fluidics Secures Another U.S. Patent for the BACTEROMIC System

0